Skip to main content
Equibles
PASG logo

PASG · Passage BIO, Inc. · Documents

Track PASG — free

Use PASG with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research PASG.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$4.01 +0.01 (+0.25%) At close · Nov 12 Q4 2022 earnings call transcript
Rebalance outlook locked
Going-concern doubt — flagged Aug 10, 2026

Substantial doubt about the company's ability to continue as a going concern.

“As a result, there is substantial doubt about the Company's ability to continue as a going concern within one year after the date that these consolidated financial statements are issued.”
View the 10-Q filed Aug 10, 2026
Market Cap
$12.90M
Shares
3.22M
Volume · Nov 12 12.63K Avg daily vol (3M) 20.62K

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Net loss $45.52M 10-K filed Mar 3, 2026 Quarterly report New FY2026 Q3 Net loss $4.72M 10-Q filed Nov 10, 2026 Latest results Financial results 8-K filed Mar 3, 2026 Earnings call Q4 2022 earnings call Held Mar 6, 2023
2026
Nov 6
Current report 8-K Events of Nov 5
Stockholders approve Remix share issuance and reverse split

Passage Bio stockholders approved merger-related Remix share issuance, a 1-for-2 to 1-for-10 reverse split, the 2026 Equity Incentive Plan and 2026 Employee Stock Purchase Plan, merger-related executive compensation arrangements, and a name change to Remix Therapeutics, Inc.

Director or officer change, or executive pay, Shareholder vote results
6 source passages
The stockholders of record of Passage Bio voted to approve the issuance of Passage Bio Common Stock to the securityholders of Remix, pursuant to the terms of the Merger Agreement, which will (a) represent more than 20% of the shares of Passage Bio Common Stock outstanding immediately prior to the First Merger and (b) result in the change of control of Passage Bio, pursuant to Nasdaq Listing Rules 5635(a) and 5635(b), respectively. The stockholders of record of Passage Bio voted to approve an amendment to Passage Bio’s amended and restated certificate of incorporation to effect, prior to the effective time of the Second Merger (the “Effective Time”), a reverse stock split of the issued and outstanding Passage Bio Common Stock at a ratio ranging from any whole number from 1-for-2 to 1-for-10, inclusive, with the final ratio to be mutually agreed to by Passage Bio and Remix (the “Reverse Stock Split”). The stockholders of record of Passage Bio voted to approve an amendment and restatement of Passage Bio’s amended and restated certificate of incorporation (the “Proposed Restated Charter”), effective as of the Effective Time, to (i) change the name of Passage Bio to “Remix Therapeutics, Inc.” and (ii) make certain other changes as provided for in the Proxy Statement/Prospectus. The stockholders of record of Passage Bio voted to approve the adoption of the Remix Therapeutics, Inc. 2026 Equity Incentive Plan. The stockholders of record of Passage Bio voted to approve the adoption of the Remix Therapeutics, Inc. 2026 Employee Stock Purchase Plan. The stockholders of record of Passage Bio voted to approve, on a non-binding advisory basis, certain compensation arrangements for Passage Bio’s named executive officers in connection with the Mergers. Open the document at this passage
Oct 8
Registration statement S-4/A
Registration statement

Passage Bio and Remix amended their merger agreement to combine at an assumed exchange ratio of 0.1727, with Passage Bio renamed Remix Therapeutics, Inc. and expected to trade under “RMTX.” A concurrent financing is expected to generate approximately $100.0 million.

Read from the first part of this long document
Oct 5
Registration statement S-4/A
Registration statement

Passage Bio proposes mergers making Remix Therapeutics a subsidiary, rename the combined company Remix Therapeutics, and conduct a concurrent financing expected to yield approximately $100.0 million in gross proceeds. Stockholders will vote on November 5, 2026.

Read from the first part of this long document
Sep 21
Registration statement S-4/A
Registration statement

Passage Bio and Remix Therapeutics plan a two-step merger, rename the combined company Remix Therapeutics, and launch a concurrent financing expected to generate approximately $100.0 million; Remix stockholders are expected to own approximately 65% of the combined company.

Read from the first part of this long document
Apr 7
Proxy statement DEF 14A Meeting May 19, 2026
Proxy statement AI summary on its way
Mar 3
Annual report 10-K FY2025, ended Dec 31
Annual report for FY2025 AI summary on its way
Net loss $45.52M Diluted EPS -$14.35
2025
2024
Showing 1–50 of 157 documents
Key facts CIK 1787297 CUSIP 702712209 13F (30d) 25 filings 14 filers Visit website Investor relations